Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present disclosure relates to the use of des-aspartate-angiotensin I and/or its derivatives that are its metabolites for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. Specifically, the disclosure relates to the treatment of a malignant growth, an invasive growth, a tumor, a tumor metastasis, a cancer or combinations thereof and to modulate the level or effect of HSP90 or other inflammation-linked molecules in relevant tissue or blood.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I and/or its derivatives for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions.

Abstract: The use of des-aspartate-angiotensin I, its derivatives and/or analogue thereof in medicine is described. In particular, a method for the treatment and/or prophylaxis of viral infections, for inducing hypoglycaemia and/or for reducing hyperglycaemia, and/or for treatment of hypoglycaemia-related conditions is described.

Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of renal-related disorders. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of glomerulosclerosis and/or end stage renal failure and/or related conditions. The method of the present invention is preferably practised by the administration of a derivative of angiotensin I. Generally, but not exclusively, the angiotensin I derivative exhibits anti-angiotensin II properties. In a preferred embodiment, the angiotensin I is des-Aspartate-angiotensin I or a derivative, homologue or analogue thereof. The present invention further contemplates compositions for use in the treatment and/or prophylaxis of renal-related disorders such as but not limited to glomerulosclerosis and/or end stage renal failure.

Abstract: The present invention generally relates to the use of des-aspartate-angiotensin I, its derivative, a functional part and/or analogue thereof in medicine. In particular, the present invention relates to the use of des-aspartate-angiotensin I, its derivative, a functional part and/or analogue thereof, for the treatment and/or prophylaxis of viral infections, for inducing hypoglycaemia and/or for reducing hyperglycaemia, and/or for treatment of a hypoglycaemia-related condition.

Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of infarction-related cardiac injuries and disorders. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of myocardial infarction and heart failure and/or related conditions. The method of the present invention is practised by the administration of a derivative of angiotensin I. In a preferred embodiment, the angiotensin I is des-Aspartate-angiotensin I. The present invention further contemplates compositions for use in the treatment and/or prophylaxis of infarction-related cardiac injuries and disorders such as but not limited to myocardial infarction and heart failure.

Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of renal-related disorders. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of glomerulosclerosis and/or end stage renal failure and/or related conditions. The method of the present invention is preferably practised by the administration of a derivative of angiotensin I. Generally, but not exclusively, the angiotensin I derivative exhibits anti-angiotensin II properties. In a preferred embodiment, the angiotensin I is des-Aspartate-angiotensin I or a derivative, homologue or analogue thereof. The present invention further contemplates compositions for use in the treatment and/or prophylaxis of renal-related disorders such as but not limited to glomerulosclerosis and/or end stage renal failure.

Abstract: The present invention relates generally to a method for the treatment and/or prophylaxis of infarction-related cardiac injuries and disorders. More particularly, the present invention contemplates a method for the treatment and/or prophylaxis of myocardial infarction and heart failure and/or related conditions. The method of the present invention is practised by the administration of a derivative of angiotensin I. In a preferred embodiment, the angiotensin I is des-Aspartate-angiotensin I. The present invention further contemplates compositions for use in the treatment and/or prophylaxis of infarction-related cardiac injuries and disorders such as but not limited to myocardial infarction and heart failure.

Abstract: The use of des-Aspartate-angiotensin I (Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) as an anti-cardiac hypertrophic agent is described. The compound, given either intravenously or orally, prevented the development of experimentally-induced cardiac hypertrophy in rats. Its action was dose-dependent and the maximum anti-cardiac hypertrophic effect was obtained at a dose of(i) 180 ng/day when given intravenously, and (ii) 285 .mu.g/day when given orally.